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BACKGROUND
Before puberty, asthma and allergy are more common in males
than in females, but these conditions become more common in
females than in males during adulthood until around the time of
menopause.1–7 The disease severity, healthcare utilisation and
impact on health-related quality of life (HRQoL) are also considerably
higher in post-pubertal females than in males.1–7 Although the
speciﬁc mechanisms for these differences are unclear, it has been
suggested that female sex steroid hormones may have a role.1,2
Higher disease risk in females appears to follow key hormonal
transitional time points in a female’s reproductive life cycle, such as
puberty, menarche, menstruation and menopause.1,2 These hormo-
nal transitional points may increase the risk of asthma and poor
asthma outcomes in females.8–10 In contrast, external suppression of
endogenous sex hormone production with hormonal contraceptives
may improve asthma outcomes,9–14 but the evidence is
inconsistent,13,14 with evidence suggesting that hormone replace-
ment therapy (HRT) may increase the risk of poor outcomes.15–22
A clearer understanding of the role of sex steroid hormones in
the development of asthma and allergy in females and their
impact on asthma exacerbation, use of healthcare, and HRQoL will
help to provide new insights into disease mechanisms and
essential preliminary data to inform the development of primary
prevention interventions and hormonal-based management
strategies. We plan to undertake a systematic synthesis of the
evidence to provide a comprehensive, unbiased estimate of the
actual effects of sex steroid hormones on the development and
clinical expression of asthma and allergy in females.
The only relevant previous systematic review on this topic was
conﬁned to investigating the role of menopausal transition; this
review focussed on asthma incidence as the sole outcome of
interest.23 Consequently, that study does not allow a thorough
appraisal of this evidence base, given that key endogenous and
exogenous hormonal factors, as well as other essential asthma
and allergy outcomes, were not considered. There is therefore the
need to undertake a more comprehensive synthesis of the effect
of the various endogenous and exogenous hormonal factors on
the full spectrum of asthma outcomes in females.
AIMS AND OBJECTIVES
We seek to identify, critically appraise, and undertake meta-
analyses of the evidence on the role of endogenous and
exogenous sex steroid hormones in the development and clinical
expression of asthma and allergy in females, in addition to
synthesising the evidence on the effectiveness of hormonal
contraceptives and HRT for the secondary prevention of asthma.
Speciﬁc primary objectives are to synthesise and interpret the
evidence on the role of:
1. Puberty, menarche, menstruation and menstrual-related
changes, and menopause in the development of asthma and
allergy and their impact on asthma exacerbation, hospitalisa-
tion, airway function and HRQoL in females.
2. Hormonal contraceptives and HRT and their subtypes in the
development of asthma and allergy and their impact on
asthma exacerbation, hospitalisation, airway function and
HRQoL in females.
Our secondary objective is to synthesise and interpret the
evidence on the potential effectiveness of hormonal contra-
ceptives and HRT for the secondary prevention of asthma in
females.
METHODS
Types of studies
We will include the following studies: all experimental studies, including
randomised controlled trials, quasi-randomised controlled trials,
controlled-clinical trials, controlled before and after studies, and
interrupted time series design; cohort studies; case–control studies; and
cross-sectional studies. Reviews, case studies and case series, and animal
studies will, however, be excluded. For evidence on the effectiveness of
hormonal contraceptives and HRT for the secondary prevention of
asthma, we will consider only randomised controlled trials.
Participants
The participants will include all females from puberty to adulthood.
Recognising that age at puberty is deﬁned differently across cultural
contexts, we will have no ﬁxed lower age limit for puberty for this review
but will adopt deﬁnitions as given in each paper. The age limit for
adulthood will be 75 years.
Types of exposure
We will include studies that have investigated the role of puberty,
menarche, menstruation, hormonal contraceptives (combined oral contra-
ceptives and progesterone-only preparations), menopause (pre- and post-
menopause, natural and surgical menopause) and HRT (oestrogen-only,
progesterone-only, and combined oestrogen–progesterone preparations).
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Outcome measures
Primary outcomes. Our primary outcomes will include self-reported or
objectively deﬁned incidence and prevalence of asthma, asthma exacer-
bation, hospitalisation and use of asthma medication.
Secondary outcomes. Secondary outcomes will include the following:
self-reported or objectively deﬁned incidence and prevalence of wheezing,
atopic dermatitis/eczema, allergic rhinitis, urticaria, angio-oedema, food
allergy, anaphylaxis and atopic sensitisation; indicators of airway function
(forced expiratory volume in 1 s, forced expiratory ﬂow, forced vital
capacity, peak expiratory ﬂow); and measures of HRQoL.
Search strategies to identify studies
We will employ a highly sensitive search strategy to retrieve articles
meeting the review criteria. Supplementary Appendix 1 contains the
search strategies developed for MEDLINE database interfaces, which we
will adapt to search other databases. Databases to search in retrieving
relevant papers will include the following: MEDLINE, EMBASE, Cochrane
Library, ISI Web of Science, CINAHL, Scopus, Google Scholar, AMED,
PsychINFO, CAB International and WHO Global Health Library. The
databases will be searched for studies published between 1990 and
2015. Additional references will be located through searching the
references cited in identiﬁed papers, as well as searching databases of
the proceedings of international conferences, such as ISI Conference
Proceedings Citation Index and ZETOC (British Library). We will locate
unpublished and ongoing studies by searching trial registries, including
Current Controlled Trials (http://www.controlled-trials.com), ClinicalTrials.
gov (http://www.clinicaltrials.gov) and Australian and New Zealand Clinical
Trials Registry (http://www.anzctr.org.au), and by contacting a panel of
international experts in the ﬁeld. There will be no language restrictions,
and where possible we will translate literature in languages other than
English and report any literature we are unable to translate.
Screening of studies
Titles and abstracts of the retrieved articles will be checked independently
by two reviewers according to the review criteria; any discrepancies will be
resolved by consensus, and disagreements will be arbitrated by a third
reviewer. Full-text copies of potentially relevant studies will be obtained
and their eligibility for inclusion independently assessed by two reviewers;
discrepancies will be resolved by consensus, and disagreements will be
arbitrated by a third reviewer.
Data extraction and reporting
Two reviewers will independently extract relevant information and study
data onto a customised data extraction sheet, which will initially be
piloted and revised where necessary using a sample of a few of the
eligible studies. Any discrepancies in data extraction will be resolved by
discussion or arbitration by a third reviewer if agreement cannot be
reached. Descriptive tables will be used to summarise the literature and
characteristics of studies contributing to the overall evidence. The role of
each of the endogenous (puberty, menarche, menstruation and
menopause) and exogenous (hormonal contraceptives and HRT) sex
steroid hormones in the risk of the study outcomes will be reported
separately. We will use the PRISMA checklist to guide the reporting of the
review.24
Quality assessment and risk of bias
The quality of eligible studies and the potential for risk of bias will be
independently undertaken by two reviewers; any discrepancies will be
resolved by discussion or arbitration by a third reviewer. We will assess the
methodological quality of experimental studies based on the recommen-
dations of the Cochrane Handbook for Systematic Reviews of Interventions
as well as the Cochrane Effectiveness and Practice Organisation of Care
(EPOC) guidelines.25 The recommendations highlight seven domains of
focus in appraising intervention studies: sequence generation, allocation
concealment, blinding of participants and personnel, blinding of outcome
assessment, incomplete outcome data, selective outcome reporting and
other sources of bias.25 We will derive domain-speciﬁc and overall quality
grading for each study as follows: A—low risk of bias; B—moderate risk of
bias; C—high risk of bias. We will use the Effective Public Health Practice
Project (EPHPP) (www.ephpp.ca) to quality-appraise observational studies
and will also derive component-speciﬁc (i.e., suitability of the study design
for the research question; risk of selection bias; exposure measurement;
outcome assessment; and generalisability of ﬁndings) and overall grading
for each study.
Data syntheses
We will undertake a narrative synthesis of the data. In addition, for studies
deemed to be reasonably clinically, methodologically and statistically
homogeneous, we will perform meta-analyses using random-effects models.
In comparison with ﬁxed-effect meta-analysis, the random-effects model is a
more conservative approach as its underlying assumption is closer to reality,
particularly synthesising studies obtained only from the published literature,
and it incorporates potential heterogeneity between studies when calculat-
ing the pooled estimates.26 We will quantify the heterogeneity between
studies using the I2 statistic. The meta-analyses will be performed separately
for experimental and observational studies and within each study design will
also be undertaken separately for groups of studies falling into each type of
sex steroid hormonal exposure (puberty, menarche, menstruation, hormonal
contraceptives, menopause and HRT). Where possible, we will perform
subgroup analyses according to females’ background characteristics, such as
age, body mass index, smoking and other potential characteristics. We will
perform sensitivity analyses on the basis of risk of bias in the studies in order
to evaluate the robustness of our ﬁndings. We will assess evidence of
publication bias using funnel plots and statistically using Begg and Egger
tests.27,28 The meta-analyses will be performed using Stata Statistical
Software (Release 13; StataCorp LP., College Station, TX, USA).
Protocol registration
A detailed protocol for the review will be registered with the International
Prospective Register of Systematic Reviews (PROSPERO): http://www.crd.york.
ac.uk/prospero/ prior to commencing the review.
DISCUSSION
The current review will present the most comprehensive and
unbiased synthesis of the evidence relating endogenous and
exogenous sex steroid hormones to the development and clinical
expression of asthma and allergy in females. The only previous
review on the topic considered menopausal transition as the only
hormone exposure and asthma as the only outcome and therefore
does not give a clear picture of the overall evidence base.23 Key
strengths of the current review include the following: (1) synthesis
of the role of both endogenous and exogenous sex steroid
hormones; (2) presentation of the evidence for each key
hormonal transitional point and exposure (puberty, menarche,
menstruation, use of hormonal contraceptives, menopause
and use of HRT) during the female’s life course and assessment
of how each of these exposure deﬁnitions inﬂuences the
risk of asthma in females; and (3) a comprehensive and highly
sensitive search strategy and inclusion of known leading
databases and a panel of expert contacts that will ensure that
the main sources of retrieving literature for the underlying
evidence are covered.
In ascertaining whether endogenous and exogenous sex steroid
hormones have any role in the development and clinical
expression of asthma and allergy in females, we aim to uncover
the following: (1) putative role and critical time windows of the
effect of each endogenous sex steroid hormone (puberty,
menarche, menstruation and menopause); (2) effectiveness and
safety of exogenous hormonal contraceptives and HRT and their
subtypes as secondary prevention strategies; (3) subgroups of
females who are more likely to beneﬁt or could be at greater risk
of asthma as a consequence of their sex steroid hormonal status
or exposure; and (4) key research gaps in this evidence base,
recommending steps to strengthen future work. Along these lines,
the evidence from this study will in particular form the basis for
initiating intervention trials to establish whether hormonal
contraceptives and HRT can be effective in improving outcomes
of asthma and allergic disorders in females.
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Conclusion
Synthesising the evidence that has so far emerged on the role of
sex steroid hormones in the development and clinical expression of
asthma and allergy in females will help to clarify the reason for
the observed sex differentials in the onset and overall burden of
asthma after puberty. Furthermore, a comprehensive synthesis of
the evidence base will provide the opportunity to identify the
potentials of exogenous sex steroid hormones for the primary and
secondary prevention of asthma in females.
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